Evidence map›Paper›PMID 32583562›Full record

ArticleFEBS open bio2020

Puromycin aminonucleoside-induced podocyte injury is ameliorated by the Smad3 inhibitor SIS3.

Lina Jiang, Hong Cui, Jie Ding, Aijun Yang, Yingchao Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FEBS open bio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Therapeutic potential for renal fibrosis by targeting Smad3-dependent noncoding RNAs.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Review
  5. The Perspective of Vitamin D on suPAR-Related AKI in COVID-19.International journal of molecular sciences · 2022
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Lina JiangPediatric Department, Beijing Friendship Hospital, Capital University of Medical Sciences, Beijing, China.
Hong CuiPediatric Department, Beijing Friendship Hospital, Capital University of Medical Sciences, Beijing, China.
Jie DingPediatric Department, Peking University First Hospital, Beijing, China.
Aijun YangPediatric Department, Beijing Friendship Hospital, Capital University of Medical Sciences, Beijing, China.
Yingchao ZhangPediatric Department, Beijing Friendship Hospital, Capital University of Medical Sciences, Beijing, China.ORCID 0000-0002-0448-8475
Beijing Friendship Hospital · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Smad3 signaling and transgelin expression are often activated during puromycin aminonucleoside (PAN)-induced podocyte injury. Here, we investigated whether the Smad3 inhibitor SIS3 can ameliorate damage to injured podocytes. A model of PAN-induced podocyte injury was constructed using the MPC5 cell line. The effects of SIS3 on the expression of the podocyte cytoskeletal proteins transgelin, p15

Indexed as

AnimalsCells, CulturedIsoquinolinesMicePodocytesPuromycin AminonucleosidePyridinesPyrrolesSmad3 Protein6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochlorideIsoquinolinesPuromycin AminonucleosidePyridinesPyrrolesSmad3 ProteinSmad3 protein, mousepodocyte injurypuromycin aminonucleosidesmad3transgelin

Identifiers

PMID32583562
PMCPMC7396432
OpenAlexW3037958321

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.